MedPath

BIOPHYTIS

🇫🇷France
Ownership
-
Employees
-
Market Cap
-
Website

Testing the Efficacy and Safety of BIO101 for the Prevention of Respiratory Deterioration in COVID-19 Patients

Phase 2
Terminated
Conditions
SARS-CoV2
Covid-19
Interventions
Drug: Placebo
First Posted Date
2020-07-15
Last Posted Date
2023-05-15
Lead Sponsor
Biophytis
Target Recruit Count
238
Registration Number
NCT04472728
Locations
🇺🇸

University of California, Irvine, Irvine, California, United States

🇺🇸

United Health Services Hospitals, Johnson City, New York, United States

🇧🇪

CHU Saint-Pierre, Brussel, Belgium

and more 19 locations

A Double-blind, Placebo-controlled, Randomized INTerventional Clinical Trial (SARA-INT)

Phase 2
Completed
Conditions
Sarcopenia
Gait Disorders in Old Age
Muscle Weakness
Interventions
Drug: Placebo
First Posted Date
2018-03-02
Last Posted Date
2024-10-01
Lead Sponsor
Biophytis
Target Recruit Count
233
Registration Number
NCT03452488
Locations
🇺🇸

PANAX Clinical Research, Miami Lakes, Florida, United States

🇺🇸

Jean Mayer USDA Human Nutrition research Center on Aging Tufts University, Boston, Massachusetts, United States

🇧🇪

Vrije Universiteit Brussel, Bruxelles, Belgium

and more 17 locations

An OBServational Clinical Trial (SARA-OBS) in Sarcopenia and Sarcopenic Obesity in Patients Aged 65 Years and Over

Completed
Conditions
Muscle Weakness
Sarcopenia
Gait Disorders in Old Age
First Posted Date
2017-01-16
Last Posted Date
2020-07-13
Lead Sponsor
Biophytis
Target Recruit Count
218
Registration Number
NCT03021798
Locations
🇧🇪

Université de Liège, Liège, Belgium

🇺🇸

Institut On Aging, Gainesville, Florida, United States

🇺🇸

Columbia University New York, New York, New York, United States

and more 4 locations
© Copyright 2025. All Rights Reserved by MedPath